A Study of SAT-3247 to Evaluate the Safety, Tolerability, and Efficacy in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
This is a two-part, Phase 2, randomized, placebo-controlled, double-blind study, followed by a randomized active treatment period, to evaluate the safety and efficacy of orally administered forazapadin (SAT-3247) in adult participants with FSHD
Epistemonikos ID: 3e8878a6eb01528b7f88cf0e3e6a3b3781bb3e20
First added on: Oct 14, 2026